Saturday, July 11, 2026

pharma · Encephalitis · Japanese Encephalitis

Valneva USA

Valneva USA drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Bethesda, USA HQ
2017 Founded
9 Employees
EMA registrant Type
Company details
Status
Public
HQ
Bethesda, USA
Founded
2017
Employees
9
Programs
2
Drugs
1
Patents
0
Intelligence · Drug Pipeline

Valneva USA pipeline

Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Valneva USA drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

1 compounds
  1. japanese encephalitis vaccine (inactivated, adsorbed)

    Antiinfectives for systemic use (J07)

    Antiinfectives for systemic use (J07) compound in Valneva USA's portfolio. Mechanism: Biological vaccine - induces immune response.

    Mechanism
    Biological vaccine - induces immune response